Johnson & Johnson’s Janssen has announced a research study using the Apple watch to help improve atrial fibrillation (AFib) outcomes, including stroke prevention, intending to to collaborate with Apple to assess the impact of the wearable technology on earlier detection of AFib, improved diagnosis and patient outcomes.
Novartis and the University of Oxford’s Big Data Institute have announced that they are to establish a five-year research alliance using artificial intelligence to understand complex diseases and improve drug development.
CRISPR has the potential to transform a variety of scientific areas, but this genome editing technique is also shrouded in controversy, particularly regarding its potential use to create genetically engineered humans.
The traditional pharma industry is eyeing the rise of Digital Therapeutics as patient outcomes fast become the only metric to sweat over. Their combined effect is setting the scene for a radical transformation of the industry. Its survival as a dominant force in shaping healthcare will depend on how it responds.